aTyr Pharma, Inc. (ATYR) News
Follow aTyr Pharma, Inc. (ATYR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
aTyr Pharma’s Efzofitimod Misses Primary Endpoint in Phase 3 Trial
aTyr Pharma said efzofitimod missed the primary endpoint in its Phase 3 pulmonary sarcoidosis trial.
EQUITY | Oct 29, 2026, 12:14 PM UTC
L
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
EQUITY | Oct 19, 2026, 11:00 AM UTC
L
aTyr Pharma study reports anti-fibrotic effects of ATYR0101
A publication in the Journal of Biological Chemistry demonstrates anti-fibrotic effects of ATYR0101.
EQUITY | Oct 13, 2026, 12:00 PM UTC
L
Weekly Recap: Phase 3 set for efzofitimod and 60% staff cut, $58.9M cash
aTyr Pharma, Inc. (NASDAQ:ATYR) won FDA alignment for a Phase 3 efzofitimod trial in pulmonary sarcoidosis—54 weeks, ~372 patients with FVC at week 48 primary—and despite a ~60% staff cut and shares near $0.35, it holds
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
aTyr Pharma aligns with FDA on Phase 3 efzofitimod study in pulmonary sarcoidosis
aTyr Pharma announced FDA alignment on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis and plans to start study activities in Q4 2026.Key Highlights:Original SEC Filing: aTYR PHARMA INC [ ATYR ] - 8-K
REGULATION | Sep 24, 2026, 01:05 PM UTC
L
aTyr Pharma, Inc. (ATYR) Aligns With FDA on Phase 3 Efzofitimod Study
aTyr Pharma aligned with FDA on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis using FVC at week 48 as the primary endpoint; study activities are expected to begin in Q4 2026 and will require addition
REGULATION | Sep 24, 2026, 10:01 AM UTC
L
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
ATYR - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
REGULATION | Sep 24, 2026, 10:00 AM UTC
L
aTyr Pharma updates timing for Phase 3 efzofitimod study response
aTyr Pharma said it will provide an update on the timing of the regulatory response for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
EQUITY | Sep 01, 2026, 08:40 PM UTC